New vaccines for tuberculosis

The Lancet

Volumn 375, Issue 9731, 2010, Pages 2110-2119

  Kaufmann, Stefan HE ^a   Hussey, Gregory ^b   Lambert, Paul Henri ^c  

^a MAX PLANCK INSTITUTE FOR INFECTION BIOLOGY   (Germany)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS ANTIGEN 85A VACCINE; AERAS 402 VACCINE; AERAS 404 VACCINE; BCG VACCINE; H1 CAF01 VACCINE; H1 IC31 VACCINE; LIVE VACCINE; M VACCAE VACCINE; M72 VACCINE; MODIFIED VACCINIA ANKARA 85A VACCINE; RECOMBINANT BCG30 VACCINE; RUTI VACCINE; UNCLASSIFIED DRUG; VPM 1002 VACCINE;

ATTENUATION; BCG VACCINATION; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNE RESPONSE; IMMUNITY; INCIDENCE; LONG TERM CARE; POSTPRIMARY TUBERCULOSIS; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TUBERCULOSIS; TUBERCULOSIS CONTROL;

EID: 77953293660     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(10)60393-5     Document Type: Review

References (81)

1. Kaufmann S., and McMichael A.J. Annulling a dangerous liaison: vaccination strategies against AIDS and tuberculosis. Nat Med 11 suppl 4 (2005) S33-S44
2. Kaufmann S. Envisioning future strategies for vaccination against tuberculosis. Nat Rev Immunol 6 (2006) 699-704
3. Kaufmann S. Recent findings in immunology give tuberculosis vaccines a new boost. Trends Immunol 26 (2005) 660-667
4. Young D., and Dye C. The development and impact of tuberculosis vaccines. Cell 124 (2006) 683-687
5. Ulrichs T., and Kaufmann S. New insights into the function of granulomas in human tuberculosis. J Pathol 208 (2006) 261-269
6. Calmette A., Guérin C., Boquet A., and Négre L. Prophylactic vaccination against tuberculosis using "BCG" (1927), Masson, Paris (in French).
7. Kaufmann S.H. Immunology's foundation: the 100-year anniversary of the Nobel Prize to Paul Ehrlich and Elie Metchnikoff. Nat Immunol 9 (2008) 705-712
8. Kaufmann S.H. The contribution of immunology to the rational design of novel antibacterial vaccines. Nat Rev Microbiol 5 (2007) 491-504
9. Ishii K.J., and Akira S. Toll or toll-free adjuvant path toward the optimal vaccine development. J Clin Immunol 27 (2007) 363-371
10. Cooper A.M. Cell-mediated immune responses in tuberculosis. Annu Rev Immunol 27 (2009) 393-422
11. Russell D.G. Who puts the tubercle in tuberculosis?. Nat Rev Microbiol 5 (2007) 39-47
12. van der Wel N., Hava D., Houben D., et al. M tuberculosis and M leprae translocate from the phagolysosome to the cytosol in myeloid cells. Cell 129 (2007) 1287-1298
13. Winau F., Hegasy G., Kaufmann S., and Schaible U.E. No life without death-apoptosis as prerequisite for T cell activation. Apoptosis 10 (2005) 707-715
14. Mosmann T.R., and Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 17 (1996) 138-146
15. Dorhoi A., and Kaufmann S.H. Fine-tuning of T cell responses during infection. Curr Opin Immunol 21 (2009) 367-377
16. Akira S., Uematsu S., and Takeuchi O. Pathogen recognition and innate immunity. Cell 124 (2006) 783-801
17. Khader S.A., Bell G.K., Pearl J.E., et al. IL-23 and IL-17 in the establishment of protective pulmonary CD4(+) T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol 8 (2007) 369-377
18. Korn T., Bettelli E., Oukka M., and Kuchroo V.K. IL-17 and Th17 Cells. Annu Rev Immunol 27 (2009) 485-517
19. Belkaid Y., and Tarbell K. Regulatory T cells in the control of host-microorganism interactions (*). Annu Rev Immunol 27 (2009) 551-589
20. Stenger S., Hanson D.A., Teitelbaum R., et al. An antimicrobial activity of cytolytic T cells mediated by granulysin. Science 282 (1998) 121-125
21. Williams M.A., and Bevan M.J. Effector and memory CTL differentiation. Annu Rev Immunol 25 (2007) 171-192
22. Sallusto F., Geginat J., and Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 22 (2004) 745-763
23. Foulds K.E., Wu C.Y., and Seder R.A. Th1 memory: implications for vaccine development. Immunol Rev 211 (2006) 58-66
24. Mora J.R., and von Andrian U.H. T-cell homing specificity and plasticity: new concepts and future challenges. Trends Immunol 27 (2006) 235-243
25. Keir M.E., Butte M.J., Freeman G.J., and Sharpe A.H. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26 (2008) 677-704
26. Azzopardi P., Bennett C.M., Graham S.M., and Duke T. Bacille Calmette-Guerin vaccine-related disease in HIV-infected children: a systematic review. Int J Tuberc Lung Dis 13 (2009) 1331-1344
27. Hesseling A.C., Marais B.J., Gie R.P., et al. The risk of disseminated Bacille Calmette-Guerin (BCG) disease in HIV-infected children. Vaccine 25 (2007) 14-18
28. WHO. Revised BCG vaccination guidelines for infants at risk for HIV infection. Wkly Epidemiol Rec 82 (2007) 193-196
29. Hesseling A.C., Cotton M.F., Marais B.J., et al. BCG and HIV reconsidered: moving the research agenda forward. Vaccine 25 (2007) 6565-6568
30. Mansoor N., Scriba T.J., de Kock M., et al. HIV-1 infection in infants severely impairs the immune response induced by Bacille Calmette-Guerin vaccine. J Infect Dis 199 (2009) 982-990
31. Fine P. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 346 (1995) 1339-1345
32. Kaufmann S. The new plagues: pandemics and poverty in a globalized world (2009), Haus Publishing, London
33. Wilson M.E., Fineberg H.V., and Colditz G.A. Geographic latitude and the efficacy of bacillus Calmette-Guerin vaccine. Clin Infect Dis 20 (1995) 982-991
34. Weir R.E., Black G.F., Nazareth B., et al. The influence of previous exposure to environmental mycobacteria on the interferon-gamma response to bacille Calmette-Guerin vaccination in southern England and northern Malawi. Clin Exp Immunol 146 (2006) 390-399
35. Hatherill M., Adams V., Hughes J., et al. The potential impact of helminth infection on trials of novel tuberculosis vaccines. Vaccine 27 (2009) 4743-4744
36. StopTB Partnership Working Group on New TB Vaccines. Tuberculosis vaccine candidates (2009). http://www.stoptb.org/wg/new_vaccines/assets/documents/TB%20Vaccine%20Pipeline%202009.pdf (accessed Feb 19, 2010).
37. Betts J.C., Lukey P.T., Robb L.C., McAdam R.A., and Duncan K. Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling. Mol Microbiol 43 (2002) 717-731
38. Voskuil M.I., Schnappinger D., Visconti K.C., et al. Inhibition of respiration by nitric oxide induces a Mycobacterium tuberculosis dormancy program. J Exp Med 198 (2003) 705-713
39. Wayne L.G., and Sohaskey C.D. Nonreplicating persistence of Mycobacterium tuberculosis. Annu Rev Microbiol 55 (2001) 139-163
40. Tullius M.V., Harth G., Maslesa-Galic S., Dillon B.J., and Horwitz M.A. A replication-limited recombinant Mycobacterium bovis BCG vaccine against tuberculosis designed for human immunodeficiency virus-positive persons is safer and more efficacious than BCG. Infect Immun 76 (2008) 5200-5214
41. Grode L., Seiler P., Baumann S., et al. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guérin mutants that secrete listeriolysin. J Clin Invest 115 (2005) 2472-2479
42. Winau F., Weber S., Sad S., et al. Apoptotic vesicles crossprime CD8 T cells and protect against tuberculosis. Immunity 24 (2006) 105-117
43. Torchinsky M.B., Garaude J., Martin A.P., and Blander J.M. Innate immune recognition of infected apoptotic cells directs T(H)17 cell differentiation. Nature 458 (2009) 78-82
44. Martin C., Williams A., Hernandez-Pando R., et al. The live Mycobacterium tuberculosis phoP mutant strain is more attenuated than BCG and confers protective immunity against tuberculosis in mice and guinea pigs. Vaccine 24 (2006) 3408-3419
45. Verreck F.A., Vervenne R.A., Kondova I., et al. MVA.85A boosting of BCG and an attenuated, phoP deficient M tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques. PLoS One 4 (2009) e5264
46. Sambandamurthy V.K., Derrick S.C., Hsu T., et al. Mycobacterium tuberculosis DeltaRD1 DeltapanCD: a safe and limited replicating mutant strain that protects immunocompetent and immunocompromised mice against experimental tuberculosis. Vaccine 24 (2006) 6309-6320
47. Lingnau K., Riedl K., and von Gabain A. IC31 and IC30, novel types of vaccine adjuvant based on peptide delivery systems. Expert Rev Vaccines 6 (2007) 741-746
48. Dietrich J., Andersen C., Rappuoli R., Doherty T.M., Jensen C.G., and Andersen P. Mucosal administration of Ag85B-ESAT-6 protects against infection with Mycobacterium tuberculosis and boosts prior bacillus Calmette-Guerin immunity. J Immunol 177 (2006) 6353-6360
49. Aagaard C., Dietrich J., Doherty M., and Andersen P. TB vaccines: current status and future perspectives. Immunol Cell Biol 87 (2009) 279-286
50. van Dissel J.T., Arend S.M., Prins C., et al. Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naïve human volunteers. Vaccine 28 (2010) 3571-3581
51. Dietrich J., Aagaard C., Leah R., et al. Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy. J Immunol 174 (2005) 6332-6339
52. Von Eschen K., Morrison R., Braun M., et al. The candidate tuberculosis vaccine Mtb72F/AS02A: tolerability and immunogenicity in humans. Hum Vaccin 5 (2009) 475-482
53. McShane H., Pathan A.A., Sander C.R., et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med 10 (2004) 1240-1244
54. Sander C.R., Pathan A.A., Beveridge N.E., et al. Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals. Am J Respir Crit Care Med 179 (2009) 724-733
55. Rooney J.F., Wohlenberg C., Cremer K.J., Moss B., and Notkins A.L. Immunization with a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: long-term protection and effect of revaccination. J Virol 62 (1988) 1530-1534
56. Radosevic K., Wieland C.W., Rodriguez A., et al. Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferon. Infect Immun 75 (2007) 4105-4115
57. Santosuosso M., McCormick S., Zhang X., Zganiacz A., and Xing Z. Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis. Infect Immun 74 (2006) 4634-4643
58. Bangari D.S., and Mittal S.K. Development of nonhuman adenoviruses as vaccine vectors. Vaccine 24 (2006) 849-862
59. Menozzi F.D., Rouse J.H., Alavi M., et al. Identification of a heparin-binding hemagglutinin present in mycobacteria. J Exp Med 184 (1996) 993-1001
60. Pethe K., Alonso S., Biet F., et al. The heparin-binding haemagglutinin of M tuberculosis is required for extrapulmonary dissemination. Nature 412 (2001) 190-194
61. Rouanet C., Debrie A.S., Lecher S., and Locht C. Subcutaneous boosting with heparin binding haemagglutinin increases BCG-induced protection against tuberculosis. Microbes Infect 11 (2009) 995-1001
62. Locht C., Hougardy J.M., Rouanet C., Place S., and Mascart F. Heparin-binding hemagglutinin, from an extrapulmonary dissemination factor to a powerful diagnostic and protective antigen against tuberculosis. Tuberculosis (Edinb) 86 (2006) 303-309
63. Rook G.A., and Stanford J.L. The Koch phenomenon and the immunopathology of tuberculosis. Curr Top Microbiol Immunol 215 (1996) 239-262
64. Dlugovitzky D., Fiorenza G., Farroni M., Bogue C., Stanford C., and Stanford J. Immunological consequences of three doses of heat-killed Mycobacterium vaccae in the immunotherapy of tuberculosis. Respir Med 100 (2006) 1079-1087
65. Stanford J., Stanford C., and Grange J. Immunotherapy with Mycobacterium vaccae in the treatment of tuberculosis. Front Biosci 9 (2004) 1701-1719
66. Von Reyn C.F., Mtei L., Arbeit R., et al. Prevention of tuberculosis in Bacille Calmette-Guérin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine. AIDS 24 (2010) 675-685
67. Cardona P.J. RUTI: a new chance to shorten the treatment of latent tuberculosis infection. Tuberculosis (Edinb) 86 (2006) 273-289
68. Vilaplana C., Montane E., Pinto S., et al. Double-blind, randomized, placebo-controlled phase I clinical trial of the therapeutical antituberculous vaccine RUTI. Vaccine 28 (2009) 1106-1116
69. Lin M.Y., and Ottenhoff T.H. Not to wake a sleeping giant: new insights into host-pathogen interactions identify new targets for vaccination against latent Mycobacterium tuberculosis infection. Biol Chem 389 (2008) 497-511
70. Wallis R.S., Pai M., Menzies D., et al. Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice. Lancet (2010) 10.1016/S0140-6736(10)60359-5 published online May 19.
71. Parida S.K., and Kaufmann S.H. The quest for biomarkers in tuberculosis. Drug Discov Today 15 (2010) 148-157
72. World Medical Association. Declaration of Helsinki-ethical principles for medical research involving human subjects (1964-2008). http://www.wma.net/en/30publications/10policies/b3/index.html (accessed Feb 9, 2010).
73. Brennan M.J., Fruth U., Milstien J., Tiernan R., de Andrade N.S., and Chocarro L. Development of new tuberculosis vaccines: a global perspective on regulatory issues. PLoS Med 4 (2007) e252
74. Minnies D., Hawkridge T., Hanekom W., Ehrlich R., London L., and Hussey G. Evaluation of the quality of informed consent in a vaccine field trial in a developing country setting. BMC Med Ethics 9 (2008) 15
75. Treatment Action Group. Tuberculosis research and development: 2009 report on tuberculosis research funding trends, 2005-2008 (2009), Treatment Action Group, New York, NY
76. Moran M., Guzman J., Ropars A.-L., et al. Neglected disease research and development: how much are we really spending? (2008), George Institute for International Health, London, UK
77. Agarwal N. A critical analysis of funding trends 2005-2007: an update (2009), Treatment Action Group, New York, NY
78. Kaufmann S., and Parida S. Changing funding patterns in tuberculosis. Nat Med 13 (2007) 299-303
79. GAVI Alliance and World Bank. Consultation and advisory process: advance market commitment for pneumococcal vaccines (April 20, 2009). http://www.vaccineamc.org/files/amcconsultationreportdec.pdf (accessed Feb 9, 2010).
80. Dye C., and Williams B.G. Eliminating human tuberculosis in the twenty-first century. J R Soc Interface 5 (2008) 653-662
81. Abu-Raddad L.J., Sabatelli L., Achterberg J.T., et al. Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics. Proc Natl Acad Sci USA 106 (2009) 13980-13985